I5NP for Prophylaxis of Delayed Graft Function in Kidney Transplantation

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Quark Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00802347
First received: December 2, 2008
Last updated: March 28, 2014
Last verified: March 2014
  Purpose

The purpose of this study is to determine whether a single administration of QPI-1002 (also known as I5NP) can prevent DGF in patients undergoing deceased donor kidney transplantation. In this Phase I /II study, patients who are undergoing renal transplantation with organs from DCD donors, ECD donors or SCD donors with ≥ 24 hours of cold ischemia time who meet study entry criteria will be studied to evaluate the safety and pharmacokinetic profile of I5NP (Part A) and clinical activity of I5NP administration (Part B). Data from this study will be used to identify doses of I5NP to be used in follow-on efficacy studies.

Part A will be a randomized, dose escalation study to determine the highest or maximum tolerated dose (MTD). Part A will enroll 40 patients at approximately 20 sites; patients will be randomized to receive either I5NP or placebo in a ratio of 8:2 in each cohort (cohorts 1-4).

Part B will utilize the dose identified in Part A to further evaluate, in a double-blind manner, the safety, and clinical activity of I5NP. In Part B, up to 326 patients will participate at approximately 60 sites; up to 163 patients will be randomized to receive I5NP and up to 163 patients randomized to receive placebo.


Condition Intervention Phase
Delayed Graft Function
Other Complication of Kidney Transplant
Drug: I5NP
Drug: Saline
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Prevention
Official Title: Controlled, Randomized, Prospective, Double-Blind, Multicenter, Phase I/II, Dose-Escalation Study of the Safety, PK, and Clinical Activity of I5NP for Prophylaxis of Delayed Graft Function in Patients Undergoing Deceased Donor Kidney Transplantation

Resource links provided by NLM:


Further study details as provided by Quark Pharmaceuticals:

Primary Outcome Measures:
  • Part A: The outcome measure is safety. Additionally, plasma blood levels will be measured to characterize the PK of I5NP in this patient population. Part B: The outcome measure will be safety and the incidence of delayed graft function. [ Time Frame: Part A: DSMB review at conclusion of each cohort / Part B: Interim analyses will be performed after the 66th, 130th, and 196th patient enrolled ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Part B: Treatment differences in the rate of improvement in renal function over time and treatment differences in the need for renal replacement therapy. [ Time Frame: Part B: Interim analyses will be performed after the 66th, 130th, and 196th patient enrolled ] [ Designated as safety issue: No ]

Estimated Enrollment: 366
Study Start Date: December 2008
Estimated Study Completion Date: June 2014
Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: I5NP Drug: I5NP

Single IV injection of I5NP

Part A: dose-escalation study; cohort 1 = 0.5 mg/kg; cohort 2 = 1.5 mg/kg; cohort 3 = 5.0 mg/kg; cohort 4 = 10.0 mg/kg

Part B: 10.0 mg/kg

Other Name: QPI-1002
Placebo Comparator: Saline Drug: Saline

Single IV injection of saline

Part A: dose-escalation study; cohort 1 = 0.5 mg/kg; cohort 2 = 1.5 mg/kg; cohort 3 = 5.0 mg/kg; cohort 4 = 10.0 mg/kg

Part B: 10.0 mg/kg


Detailed Description:

Although the etiology of DGF is not fully understood and may be multifactorial, the pathophysiology appears to be primarily related to ischemia-reperfusion (IR) injury resulting from organ preservation between the times of harvesting from the donor and reperfusion following vascular reanastomosis in the recipient.

I5NP is a small interfering RNA (siRNA) that is being developed for the prophylaxis of delayed graft function (DGF) in patients receiving renal transplants.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patient is at least 18 years of age.
  2. Patient has given informed consent.
  3. Patient is willing to practice birth control. Female patients must be: (1) post-menopausal (2) surgically sterile, or (3) using an effective means of contraception (per the site-specific guidelines or using 2 methods of birth control concurrently, whichever is more stringent) which will be continued until the Study Day 90 visit with a negative pregnancy test within 48 hours prior to administration of study drug. Male patients with female partners of child bearing potential must agree to use an effective means of contraception (per the site-specific guidelines or using 2 methods of birth control concurrently, whichever is more stringent) which will be continued until the Study Day 90 visit. Note: For the purpose of this study, post menopausal is defined as the absence of menses consistent with ESRD. A woman is considered to be surgically sterilized if she has had a bilateral tubal ligation for at least 6 months prior to administration of study drug, bilateral oophorectomy, or complete hysterectomy.
  4. Women of childbearing potential test negative for pregnancy (either urine or serum) within 48 hours prior to transplant.
  5. Patient is up-to-date on cancer screening according to site-specific guidelines and the past medical history is negative for biopsy-confirmed malignancy within 5 years of randomization, with the exception of adequately treated basal cell or squamous cell carcinoma in situ.
  6. Patient is scheduled to receive kidney transplant from a deceased donor meeting the following criteria:

    Part A:

    • receipt of an extended criteria donor (ECD) kidney, or
    • receipt of a kidney donated after cardiac death (DCD), or
    • receipt of a standard criteria donor (SCD) with cold ischemia time (CIT) ≥ 24 hours.

    Part B:

    • receipt of an ECD kidney that has been preserved by cold storage (ECD/CS) for the entire period of cold ischemia time (CIT), regardless of duration
    • receipt of an ECD kidney that has been preserved by machine perfusion (ECD/MP) for any interval of time during the period of cold ischemia, where total CIT has been at least 26 hours
    • receipt of an SCD kidney that has been preserved by cold storage (SCD/CS) where total CIT has been at least 26 hours
    • receipt of an SCD kidney that has been preserved by machine perfusion (SCD/MP) for any interval of time during the period of cold ischemia, where total CIT has been at least 26 hours.
  7. Patient is dialysis dependent at the time of transplant as documented by: a) the requirement for at least 2 dialysis sessions/week during the 56 days prior to transplant, or b) the planned removal of any remaining native kidney at the time of transplant, or c) the opinion of the investigator that the patient has no remaining native renal function (Part A only), or d) the investigator has provided documentation to the Medical Monitor that the patient has no remaining native renal function (e.g., documentation that the patient is anuric, with urine output <50 mL/day) (Part B only).

Exclusion Criteria:

  1. Patient has participated in an investigational drug study in the last 30 days.
  2. Patient has known allergy or has participated in prior study with siRNA.
  3. Patient is HCV-positive
  4. Patient is HIV-positive
  5. Patient is scheduled to undergo multiorgan transplantation.
  6. Patient has a planned transplant of kidneys that are implanted en bloc (dual kidney transplant).
  7. Patient has planned transplant of kidneys from donors < 6 years of age.
  8. Patient has planned transplant of dual kidneys (from the same donor) transplanted not en bloc (as in the case of dual ECD donor kidneys).
  9. Patient is scheduled for transplantation of a kidney from a donor who is known to have received an investigational therapy (under another IND) for ischemic/reperfusion injury immediately prior to organ recovery.
  10. Patient is scheduled to receive a living donor kidney.
  11. Patient is scheduled to receive an ABO-incompatible donor kidney.
  12. Patient is scheduled to receive an organ from a donor that meets both DCD and ECD criteria.
  13. Patient is scheduled to receive an organ from a donor that meets DCD criteria (exclusion applicable to Part B only).
  14. Patient has history or presence of a medical condition or disease that in the investigator's assessment would place the patient at an unacceptable risk for study participation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00802347

  Hide Study Locations
Locations
United States, Alabama
University of Alabama Birmingham
Birmingham, Alabama, United States, 35294
United States, California
Loma Linda University Medical Center
Loma Linda, California, United States, 92354
UCLA Medical Center
Los Angeles, California, United States, 90095
University of Southern California
Los Angeles, California, United States, 90033
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
Transplant Research Institute (TRI; formerly NIT)
Los Angeles, California, United States, 90057
UC Davis Medical Center
Sacramento, California, United States, 95817
UCSF Medical Center
San Francisco, California, United States, 94143
California Pacific Medical Center
San Francisco, California, United States, 94115
United States, Colorado
University of Colorado Health Science Center
Aurora, Colorado, United States, 80045
United States, District of Columbia
Washington Hospital Center
Washington, District of Columbia, United States, 20010
United States, Florida
University of Florida
Gainesville, Florida, United States, 32610
University of Miami
Miami, Florida, United States, 33136
Lifelink Healthcare Institute
Tampa, Florida, United States, 33606
United States, Georgia
Piedmont Hospital
Atlanta, Georgia, United States, 30309
Emory University
Atlanta, Georgia, United States, 30322
United States, Illinois
University of Illinois Chicago
Chicago, Illinois, United States, 60612
Rush University
Chicago, Illinois, United States, 60612
United States, Maryland
University of Maryland
Baltimore, Maryland, United States, 21201
Johns Hopkins University
Baltimore, Maryland, United States, 21205
United States, Michigan
University of Michigan
Ann Arbor, Michigan, United States, 48109
United States, Minnesota
Mayo Clinic Rochester
Rochester, Minnesota, United States, 55905
United States, New Jersey
Saint Barnabas Medical Center
Livingston, New Jersey, United States, 07039
United States, New York
Columbia University
New York, New York, United States, 10032
Cornell University
New York, New York, United States, 10065
United States, North Carolina
Duke University
Durham, North Carolina, United States, 27710
Wake Forest University Medical Center
Winston-Salem, North Carolina, United States, 27157
United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States, 29425
United States, Texas
Baylor University Medical Center
Dallas, Texas, United States, 75246
Baylor All Saints Medical Center
Fort Worth, Texas, United States, 76104
The Methodist Hospital
Houston, Texas, United States, 77030
United States, Virginia
University of Virginia
Charlottesville, Virginia, United States, 22908
Virginia Commonwealth University (MCV)
Richmond, Virginia, United States, 23298
Canada, British Columbia
St. Paul's Hospital, Univeristy of BC
Vancouver, British Columbia, Canada
UBC - Division of Nephrology
Vancouver, British Columbia, Canada
Canada, Nova Scotia
QE II Capital District Health Authority, Halifax
Halifax, Nova Scotia, Canada
Canada, Quebec
MUHC Royal Victoria Hospital
Montreal, Quebec, Canada
France
Hôpital Pasteur
Nice, France
Hôpital Necker
Paris, France
CHU Rangueil
Toulouse, France
Germany
Charité - Universitätsmedizin Berlin
Berlin, Germany
Charité, Campus Virchow-Klinikum
Berlin, Germany
Kliniken der Stadt Köln gGmbH
Cologne, Germany
Universitätklinikum Hamburg-Eppendorf
Hamburg, Germany
Universitätsklinikum Heidelberg
Heidelberg, Germany
Universitätsmedizin Mannheim
Mannheim, Germany
Universitätsklinikum Tübingen
Tübingen, Germany
Spain
Hospital del mar
Barcelona, Spain
Hospital de bellvitge
Barcelona, Spain
Hospital Vall Hebron
Barcelona, Spain
Sponsors and Collaborators
Quark Pharmaceuticals
Investigators
Study Director: Shai Erlich, Ph.D. Quark Pharmaceuticals
  More Information

No publications provided

Responsible Party: Quark Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00802347     History of Changes
Other Study ID Numbers: QRK.006
Study First Received: December 2, 2008
Last Updated: March 28, 2014
Health Authority: United States: Food and Drug Administration
Canada: Health Canada
Germany: Federal Institute for Drugs and Medical Devices
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Spain: Agencia Española de Medicamentos y Productos Sanitarios

Keywords provided by Quark Pharmaceuticals:
Delayed Graft Function
Kidney Transplant
Renal Transplant
small interfering ribonucleic acid (siRNA)

Additional relevant MeSH terms:
Delayed Graft Function
Pathologic Processes

ClinicalTrials.gov processed this record on July 31, 2014